| Previous Close | 43.85 |
| Open | 43.84 |
| Bid | 43.04 x 2000 |
| Ask | 44.09 x 1900 |
| Day's Range | 43.06 - 43.91 |
| 52 Week Range | 36.58 - 47.82 |
| Volume | 122,103 |
| Avg. Volume | 73,634 |
| Net Assets | 451.95M |
| NAV | 43.04 |
| PE Ratio (TTM) | N/A |
| Yield | 0.61% |
| YTD Return | 10.38% |
| Beta (3y) | 1.25 |
| Expense Ratio (net) | 0.35% |
| Inception Date | 2006-06-19 |
- Market Realist•yesterday
Bristol-Myers Squibb’s 2Q17 Estimates: Expect Growth!
Bristol-Myers Squibb (BMY) is expected to report a rise of ~4.4% in its earnings to $5.1 billion for 2Q17 on July 27, 2017.
- Market Realist•3 days ago
What Analysts Recommend for Eli Lilly ahead of 2Q17 Results
Eli Lilly (LLY) surpassed Wall Street analysts’ revenue estimates of $5.21 billion with reported revenues of $5.23 billion during 1Q17.
- Market Realist•13 days ago
Understanding Allergan’s Revenue Stream for 2017
Allergan's revenues are driven by the strong performance of products under its key brands as well as the inclusion of revenues from LifeCell and other acquisitions.
